Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 3/2012

01-06-2012 | CE - LETTER TO THE EDITOR

A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score

Authors: Melina Verso, Giancarlo Agnelli, Sandro Barni, Giampietro Gasparini, Roberto LaBianca

Published in: Internal and Emergency Medicine | Issue 3/2012

Login to get access

Excerpt

The association between cancer and venous thromboembolism (VTE) is well established [1]. Indeed, up to 20 % of cancer patients have a symptomatic VTE, which is recognized to be one of the leading causes of death in these patients [2]. …
Literature
1.
Agnelli G (1997) Venous thromboembolism and cancer: a two way clinical association. Thromb Haemost 78:117–120PubMed
2.
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907PubMedCrossRef
3.
Barni S, La Bianca R, Agnelli G, Bonizzoni E, Verso M, Mandalà M, Brighenti M, Petrelli F, Bianchini C, Perrone T, Gasparini G (2011) Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 9:179–185PubMedCrossRef
4.
Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E (2009) For the PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in outpatients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10:943–949PubMedCrossRef
5.
Streiff MB, Bockenstedt PL, Cataland PR, Chesney C, Eby C, Fanikos J, Fogarty PF, Gao S, Garcia-Aguilar J, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Jones KA, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Smith JL, Yee GC, Zakarija A (2011) Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 9:714–775
Metadata
Title
A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score
Authors
Melina Verso
Giancarlo Agnelli
Sandro Barni
Giampietro Gasparini
Roberto LaBianca
Publication date
01-06-2012
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 3/2012
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-012-0784-y

Other articles of this Issue 3/2012

Internal and Emergency Medicine 3/2012 Go to the issue

IM - Original

Right ventricular function predicts cardiovascular events in outpatients with stable cardiovascular diseases: preliminary results

IM - REVIEW

Structural abnormalities of small resistance arteries in essential hypertension

IM - ORIGINAL

Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients

IM - CASE RECORD

A case of chest pain and heart failure

EM - ORIGINAL

The predictive value of physical examination findings in patients with suspected acute heart failure syndrome

IM - ORIGINAL

Aging reduces complexity of heart rate variability assessed by conditional entropy and symbolic analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits